GlassScriptPhysician profile
Timothy Everett Hwalek
NPI 1568880904
$6,456.03
in general payments reported to CMS, 2019-2025
28 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $942 · 2021: $1,808 · 2022: $770 · 2023: $708 · 2024: $924 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,936.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,722.00 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,701.50 | 2020-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.16 | 2020-2025 | Stiolto Respimat, Ofev |
| Regeneron Healthcare Solutions, INC. | $334.64 | 2022-2025 | Dupixent |
| Grifols USA, LLC | $307.34 | 2020-2024 | Prolastin-C Liquid |
| Pulmonx Corporation | $265.76 | 2020-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $214.40 | 2021-2023 | Glassia |
| Genzyme Corporation | $204.71 | 2020-2025 | |
| Axsome Therapeutics, INC. | $152.25 | 2023-2025 | Sunosi |
| United Therapeutics Corporation | $139.65 | 2021-2024 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $122.30 | 2020-2023 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $111.78 | 2024 | Inspire |
| Lilly USA, LLC | $89.98 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $85.82 | 2020-2024 | Zerbaxa, Keytruda, Recarbrio |
| Genentech USA, INC. | $73.22 | 2020-2024 | Xolair |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $69.51 | 2025 | Yupelri |
| Mylan Specialty L.P. | $63.42 | 2020-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $62.13 | 2021-2024 | |
| Gilead Sciences, INC. | $54.02 | 2021 | |
| Shionogi INC | $50.38 | 2023 | Fetroja |
| Medtronic, INC. | $49.70 | 2022 | |
| Baxter Healthcare | $38.50 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $26.24 | 2025 | Arikayce |
| Nabriva Therapeutics, Plc | $20.48 | 2021 | |
| Advanced Respiratory, INC | $18.85 | 2021 | |
| Amgen INC. | $18.25 | 2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $17.53 | 2021 | |
| Kaleo, INC. | $17.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Hwalek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.